Additional data file 6. Clinicopathological characteristics of ovarian cancer patients (“EUROPE”). Patients are stratified into patients who did receive Cisplatin-based chemotherapy (n=85) or received Carboplatin-based chemotherapy (n=121).

The third data set consisted of primary ovarian can- cer samples (n = 342, serous ovarian cancers, median 58 years at diagnosis; 316 received carboplatin-based chemotherapy with

(3) Denoted “TCGA”: Primary ovarian cancer samples (n=342, serous ovarian cancers, median 58 years at diagnosis; 316 received Carboplatin-based chemotherapy), analyzed

Clinicopathological characteristics of ovarian cancer patients (“INNSBRUCK”) for which HOTAIR expression and DNAme has been done (n=134)... * for the entire follow

** 98 and 59 patients received Carboplatin in combination with Cyclophosphamide and Paclitaxel, respectively; 10 and 8 patients received Cisplatin in combination with

Patients are stratified into patients who did receive Cisplatin-based chemotherapy (n=26) or received Carboplatin (Carboplatin-Monotherapy or combination

(A) Patients with Carboplatin treatment (B) patients without Carboplatin treatment

Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the Groningen set for a follow up period of

confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the subset of 63 Carboplatin treated ovarian